<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes	(indicate where provided:	n/a
For commercial reagents, provide			n/a
supplier name, catalogue number and			
Cell materials	Yes	(indicate where provided:	n/a
Cell lines: Provide species			n/a
information, strain. Provide accession			,
number in repository OR supplier			
name, catalog number, clone			
Primary cultures: Provide species,	-		n/a
strain, sex of origin, genetic			
Experimental animals	Vec	(indicate where provided:	n/a
Laboratory animals: Provide species,	103	(indicate where provided.	n/a
strain, sex, age, genetic modification			n/a
status Provide accession number in			
repository OR supplier name, catalog			
Animal observed in or captured from			n/a
the field: Provide species, sex and			,
age where possible			
Model organisms: Provide Accession			n/a
number in repository (where			
Plants and microbes	Yes	(indicate where provided:	n/a
Plants: provide species and strain, unique			n/a
accession number if available, and source			
(including location for collected wild			
Microbes: provide species and strain,			n/a
unique accession number if available,			, «
Human research participants	Yes	(indicate where provided:	n/a
Identify authority granting ethics approval		hods-System setup/paragraph 2	
(IRB or equivalent committee(s), provide		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
reference number for approval.			
Provide statement confirming informed	Met	hods-System setup/paragraph 2	
consent obtained from study participants.		· · · · ·	
Report on age and sex for all study	Res	ults/ paragraph 3	

<u>Design</u>

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial		n/a
registration number OR cite DOI in		
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if		n/a
detailed step-by-step protocols are		174
Experimental study design (statistics	Yes (indicate where provided:	n/a
State whether and how the following have		
been done, or if they were not carried out.		
Sample size determination	Methods-System setup/paragraph 2	
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria		n/a
Sample definition and in-laboratory	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory	Methods-System setup/paragraph 2	
Define whether data describe technical or	Methods-System setup/paragraph 2	
biological replicates		
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Methods-System setup/paragraph 2	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required,		n/a
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
		n/a
If study is subject to dual use research of		II/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the		n/a

<u>Analysis</u>

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and	Methods-IDa-OCTA algorithm/ paragraph 1	

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify	Results/ paragraph 1-3	
choice of tests.		

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are		n/a
available, including protocols for access or		
restriction on access.		
If data are publicly available, provide		n/a
accession number in repository or DOI or		
If publicly available data are reused,		n/a
provide accession number in repository or		
DOI or URL, where possible.		
Code Aveilability	Noo (indicate adams ana idada	
Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software	Table1	
essential for replicating the main findings		
State whether the code or software is		n/a
If code is publicly available, provide		n/a
accession number in repository, or DOI or		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	Introduction/ paragraph 7 Footnote/ paragraph 1	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/qims-21-1056